Pagliano F M, Galbiati G C
Medical Department, Carate Briaza Hospital, Milan, Italy.
J Int Med Res. 1995 Jul-Aug;23(4):219-27. doi: 10.1177/030006059502300401.
The efficacy and safety of two different regimens of dihydroergocristine, in the treatment of patients with chronic cerebro-vascular disease, were compared in this double-blind study. Forty out-patients, 11 males and 29 females, aged 55-80 years were randomly assigned to treatment with 6 or 20 mg dihydroergocristine, daily, for 3 months. The Sandoz Clinical Assessment for Geriatrics (SCAG) scale was used to assess the efficacy of treatment. Both doses induced a statistically significant improvement (P < 0.01) in total SCAG scores after both 45 and 90 days of treatment. The higher dose produced a significantly greater improvement in total SCAG scores than did the lower dose after both 45 and 90 days. There were no statistically or clinically significant changes in any of the laboratory parameters after either treatment; neither were there any statistically significant changes in blood-pressure or pulse-rate except in the case of standing systolic pressure which decreased significantly (P < 0.01) in the 20 mg group. The only adverse event reported was a case of mild gastric pain at the end of treatment with 20 mg dihydroergocristine.
在这项双盲研究中，比较了两种不同方案的双氢麦角汀治疗慢性脑血管疾病患者的疗效和安全性。40名门诊患者，年龄55 - 80岁，其中男性11名，女性29名，被随机分配接受每日6毫克或20毫克双氢麦角汀治疗，为期3个月。采用山德士老年临床评估量表（SCAG）评估治疗效果。治疗45天和90天后，两种剂量均使SCAG总分有统计学意义的改善（P < 0.01）。治疗45天和90天后，较高剂量组的SCAG总分改善程度均显著大于较低剂量组。两种治疗后，任何实验室参数均无统计学或临床意义的变化；除20毫克组的站立收缩压显著降低（P < 0.01）外，血压和脉搏率也无统计学意义的变化。报告的唯一不良事件是20毫克双氢麦角汀治疗结束时出现的1例轻度胃痛。
